Strategic Industry Insight: Decoding the FDA Warning Letter to Respilon Production S.R.O. and the Path to Regulatory Recovery
[中譯] 策略產業洞察：解讀對 Respilon Production S.R.O. 的 FDA 警告信及法規恢復之路

1. Strategic Context and the Compliance Imperative
[中譯] 1. 策略背景與合規的必要性

At Persimmon Engineering (台南梁山工程顧問有限公司), we recognize that the FDA’s regulatory posture has shifted from traditional site inspections toward a high-frequency, document-centric oversight model.
[中譯] 在梁山工程顧問有限公司（Persimmon Engineering），我們意識到 FDA 的監管姿態已從傳統的實地廠房稽查，轉向高頻率且以文件為核心的遠端紀錄審查模式。

The recent Warning Letter issued to Respilon Production S.R.O. is a landmark example of the FDA leveraging its authority under Section 704(a)(4) of the FD&C Act to conduct remote records reviews.
[中譯] 近期向 Respilon Production S.R.O. 發出的警告信是一個里程碑式的案例，展現了 FDA 如何利用其在 FD&C 法案第 704(a)(4) 條下的授權來進行遠端紀錄審查。

For manufacturers in Tainan and across the broader international market, this case serves as a "proxy warning": the FDA no longer needs to step foot on your factory floor to halt your exports.
[中譯] 對於台南及更廣泛國際市場的製造商而言，此案例可視為一個「代理警告」：FDA 再也無需踏入您的廠房設施，即可中止您的產品輸出。

A Warning Letter of this magnitude is a call to move beyond mere "check-box" compliance and fundamentally elevate Quality Management Systems (QMS) to meet Current Good Manufacturing Practice (CGMP) standards.
[中譯] 收到此等規模的警告信，代表著企業必須擺脫流於形式的「打勾式」合規，從根本上提升品質管理系統（QMS），以符合現行優良製造規範（CGMP）標準。

The FDA’s explicit demand for a "Qualified Consultant" under 21 CFR 211.34 underscores that internal remediation is no longer viewed as sufficient once systemic failures are exposed.
[中譯] FDA 明確要求依據 21 CFR 211.34 聘請「具備資歷的合規顧問」，這強調了一旦系統性失效被揭露，內部的自行矯正措施已被認定為不敷使用。

From a strategic perspective, external expertise is now a "defense of the license."
[中譯] 從策略角度來看，引進外部專家如今等同於「捍衛執照」的必要手段。

A consultant does not merely provide technical oversight; they serve as a third-party certifier to the Agency, providing the objective evidence required to restore regulatory trust and maintain US market access.
[中譯] 合規顧問不僅提供技術性監督；他們更充當官方的第三方認可者，提供恢復法規信任與維持美國市場准入所需的客觀實證。

The following forensic breakdown of the Respilon case details the technical failures that led to this crisis and the methodology required for a successful recovery.
[中譯] 以下對 Respilon 案例進行的鑑識級剖析，詳述了導致這場危機的技術性失效，以及成功實施法規恢復所需的關鍵策略方法。

2. Forensic Analysis of CGMP Violations in the Respilon Case
[中譯] 2. Respilon 案例中 CGMP 違規行為的鑑識分析

The FDA’s enforcement actions center on the "Identity, Strength, Quality, and Purity" (ISQP) framework.
[中譯] FDA 的法規執行行動圍繞在「鑑別、含量、品質與純度」（ISQP）架構。

When a manufacturer fails to scientifically prove these attributes, the Agency legally classifies the product as "adulterated" under Section 501(a)(2)(B).
[中譯] 當製造商無法以科學方法證明 these 關鍵品質屬性時，官方將在法律上根據第 501(a)(2)(B) 條將產品歸類為「劣藥（Adulterated）」。

This status renders the product unmarketable and exposes the firm to severe legal liability.
[中譯] 此狀態將導致產品失去上市銷售資格，並使企業面臨重大的法律責任。

Technical Breakdown of Non-Compliance Findings
[中譯] 不合規發現之技術明細

Regulatory Citation / 法規條款	Nature of Violation / 違規行為本質	The "So What?" Layer / 戰略影響層面
21 CFR 211.84(d)(1) & (2)	Failure to conduct identity testing on each component; failure to validate supplier reliability. [中譯] 未對每批組成物進行鑑別測試；未驗證供應商可靠性。	Product Integrity Risk: Without container-level testing, raw materials are unverified. This can lead to catastrophic contamination, necessitating a full market withdrawal. [中譯] 產品完整性風險：缺乏容器級別的測試，原物料處於未驗證狀態。這可能引發災難性污染，導致被迫進行全市場撤回。
21 CFR 211.166(a)	Absence of a written stability testing program to support labeled expiration dates. [中譯] 缺乏書面的安定性試驗計畫以支持標籤上登載的末效日期。	Inventory Invalidation: Lack of stability data invalidates the entire inventory currently in the U.S. market, typically triggering a voluntary recall to mitigate safety risks. [中譯] 庫存全面失效：缺乏安定性數據會使現存於美國市場的所有庫存失效，通常會引發自願性回收以降低公眾安全風險。
21 CFR 211.100(a)	Failure to establish adequate process controls or validate manufacturing reproducibility. [中譯] 未建立適當的製程管制，或未確效生產的重現性。	Legal Fiction: A process that is not validated is "legally out of control." Consequently, Batch Production Records are viewed by auditors as unreliable documentation rather than proof of quality. [中譯] 法律擬制狀態：未經過程確效的製程在法律上被判定為「失控」。因此，批生產紀錄將被稽查員視為不可信的文件，而非品質的實證。
21 CFR 211.165(e)	Failure to validate the accuracy, sensitivity, and specificity of test methods. [中譯] 未能確效檢驗方法的準確度、靈敏度與專一性。	Scientific Invalidity: If the analytical method for an active ingredient is unverified, all release data is scientifically unsound. The FDA assumes the product's quality is unknown. [中譯] 科學無效性：若主成分分析方法未經確認，所有放行數據在科學上皆站不住腳。FDA 將推定該產品的品質狀態為未知。
21 CFR 211.194(a)	Incomplete laboratory records; Certificates of Analysis (COA) omitted raw assay data. [中譯] 實驗室紀錄不全；檢驗報告書（COA）中遺漏了原始分析數據。	Data Integrity Failure: The omission of raw data is a fundamental breach of transparency. Without contemporaneous, complete records, the firm's entire quality system is deemed compromised. [中譯] 數據完整性失控：遺漏原始數據嚴重觸犯誠信透明底線。若缺乏同步且完整的紀錄，工廠的整個品質系統將被認定已遭受全面破壞。

Immediate Red Flags Identified:
[中譯] 被識別出的立即性法規紅旗：

• Lethal Impurity Oversight: The firm failed to perform USP identification tests for components at high risk for contamination with Diethylene Glycol (DEG) or Ethylene Glycol (EG).
  [中譯] 致命不純物疏漏：該工廠未對具有二甘醇（DEG）或乙二醇（EG）高污染風險的組成物執行 USP 鑑別測試。
• These are the primary drivers of current FDA 704(a)(4) scrutiny due to their history of causing mass poisoning events.
  [中譯] 鑑於這些物質曾引發多起集體中毒的歷史事件，它們已成為當前 FDA 第 704(a)(4) 條審查中的最核心控管項目。
• Assumptions vs. Empirical Data: The firm claimed microbial proliferation was "not possible" based on water activity being "less than (b)(4)."
  [中譯] 假設凌駕於科學實證：該廠僅憑水活性「低於 (b)(4)」即宣稱微生物繁殖「絕無可能」。
• The FDA rejected this because the claim was based on assumptions rather than a comprehensive microbial risk assessment or validated stability data.
  [中譯] FDA 駁回了這一論點，因為該主張純屬主觀假設，並非基於全面性的微生物風險評估或經確效的安定性數據。
• Methodological Inadequacy: Utilizing analytical methods for active ingredients that lacked demonstrated specificity or robustness, essentially making "Pass" results on a COA meaningless.
  [中譯] 分析方法缺陷：所使用的主成分分析方法缺乏經證實的專一性或健壯性，這使得檢驗報告書上的「合格」結論變得毫無實質意義。

3. Evaluative Impact: Commercial Risks and Market Barriers
[中譯] 3. 衝擊評估：商業風險與市場壁壘

An FDA Warning Letter is a public indictment that disrupts the global supply chain.
[中譯] FDA 警告信是一項公開的官方譴責，足以癱瘓全球供應鏈。

For Respilon, the consequences are immediate and punitive, serving as a cautionary tale for any firm neglecting the technical requirements of the US market.
[中譯] 對於 Respilon 而言，後續影響是立即且具懲罰性的，這對任何漠視美國市場技術要求的企業均是深刻的警示。

The Consequences of Non-Compliance:
[中譯] 不合規所導致的嚴重後果：

Operational Disruption:
[中譯] 營運層面之中斷：

• Withholding of Approvals: The FDA may stop approving any new drug applications (ANDAs/NDAs) or supplements listing the Brno facility until compliance is verified.
  [中譯] 凍結審查批准：在合規狀態獲得重新驗證前，FDA 將拒絕批准任何將該布爾諾（Brno）廠列入其中的新藥申請（ANDA/NDA）或補充申請。
• Mandatory Re-inspection: Compliance status is only restored after a successful follow-up inspection, a process that can take months or years.
  [中譯] 強制性重檢：唯有在通過實地追蹤稽查並取得完全認可後，合規狀態才能獲得恢復，此程序往往耗時數月至數年之久。

Legal/Financial Liability:
[中譯] 法律與財務責任：

• Section 801(a)(3) Import Detention: Products are likely to be detained at the border without physical examination ("DWPE"), effectively ending the firm’s US revenue stream.
  [中譯] 第 801(a)(3) 條邊境扣押：產品極可能在海關即面臨「無需實體檢驗之扣押（DWPE）」，實質上切斷該企業在美國的所有營收來源。
• Erosion of Trust: A Certificate of Analysis (COA) that only states "PASSED" without providing raw assay data is viewed as a "transparency gap."
  [中譯] 信任瓦解：僅簡略註明「合格」卻未能提供原始檢驗數據的分析證明書，被認定為重大的「透明度斷層」。
• This lack of data integrity causes the FDA to lose all confidence in the firm's Laboratory Control System.
  [中譯] 這種數據完整性的匱乏，將導致 FDA 完全喪失對該廠實驗室管制系統的信心。

4. The 15-Day Rapid Response Framework: Persimmon Engineering’s Methodology
[中譯] 4. 15日黃金應變架構：梁山工程顧問有限公司的應對技術

The 15-working-day window following a Warning Letter is the most critical period in a firm's history.
[中譯] 收到警告信後的 15 個工作天，是企業存亡最為關鍵的黃金期。

Persimmon Engineering utilizes this window to pivot a manufacturer from a state of crisis to a state of remediation through a high-intensity protocol.
[中譯] 梁山工程顧問有限公司（Persimmon Engineering）善用此時間視窗，透過高強度的應變規程，協助藥廠從危機狀態迅速跨越至系統化補強階段。

Regulatory Recovery Roadmap:
[中譯] 法規恢復策略路線圖：

• Immediate Gap Analysis & Retrospective Review: We lead an investigation into the root causes of the citations.
  [中譯] 即時差異分析與回溯性審查：我們主導深入調查以揪出不合規項目的根本原因。
• Crucially, we initiate a Retrospective Review of all batches currently in distribution within the U.S. that are within their labeled shelf life to assess the need for immediate safety actions.
  [中譯] 至關重要的是，我們針對所有目前在美流通且仍在有效期限內的產品批次啟動「回溯性審查」，以科學評估是否需要立即採取安全回收手段。
• Consultant Integration & Certification: Per 21 CFR 211.34, Persimmon Engineering serves as the lead technical expert.
  [中譯] 合規顧問整合與認可：依據 21 CFR 211.34 規範，梁山工程工程團隊將擔任首席技術專家。
• We do not just consult; we certify the remediation efforts to the FDA, acting as the primary interlocutor with the Office of Manufacturing Quality.
  [中譯] 我們不只提供諮詢，更向 FDA 具名認可整改成果，扮演廠方與製造品質辦公室之間的核心對話窗口。
• Strategic CAPA Implementation: We develop a comprehensive Corrective and Preventive Action (CAPA) plan.
  [中譯] 策略性 CAPA 執行：我們制定全方位的矯正與預防措施（CAPA）計畫書。
• For complex remediations, we establish a rigorous "schedule for completion" with milestones that demonstrate continuous progress to the Agency.
  [中譯] 針對高度複雜的整改項目，我們確立嚴格的「完成時程表」並設立里程碑，向官方展現持續推進的合規進度。
• The Six-System Audit: The FDA mandates a comprehensive audit of the firm's entire operation.
  [中譯] 六大系統稽核：FDA 強制要求對藥廠進行全面的營運審查。
• In the Respilon case, the Laboratory Control System and the Quality System are the primary points of failure.
  [中譯] 在 Respilon 案例中，實驗室管制系統與品質系統是核心崩潰點。
• Persimmon Engineering focuses on fortifying these core systems, knowing that failures here inevitably cascade into the Production, Materials, Facilities, and Packaging systems.
  [中譯] 梁山工程集中資源強化此兩大核心系統，因我們深知此處的缺失必然會連帶引發後續生產、物料、廠房設施及包裝系統的全面連鎖潰敗。

5. Potential Risk Solutions and Future-Proofing Compliance
[中譯] 5. 潛在風險解決方案與前瞻性合規建構

Transitioning to proactive "quality-by-design" is the only way to avoid the cycle of Warning Letters.
[中譯] 唯有轉型至前瞻性的「品質源於設計（QbD）」，方能徹底終結陷入警告信的無限惡性循環。

Persimmon Engineering implements three Strategic Remediation Pillars:
[中譯] 梁山工程顧問團隊全面推行三大核心策略整改支柱：

• Pillar 1: Robust Component Qualification: We mandate identity testing for every container of each lot unless a rigorous, validated supplier reliability program is in place (21 CFR 211.84).
  [中譯] 支柱一：嚴格的組成物資格驗證：除非具備經嚴密確效的供應商可靠性計畫，否則強制要求對每批原物料的「每一個容器」執行鑑別測試（21 CFR 211.84）。
• This specifically includes screening for high-risk impurities like DEG and EG.
  [中譯] 這特別涵蓋了針對 DEG 和 EG 等高危險性不純物的關鍵篩檢。
• Pillar 2: Life-Cycle Process Validation: We implement Process Performance Qualification (PPQ) protocols.
  [中譯] 支柱二：生命週期過程確效：我們導入製程性能驗證（PPQ）計畫書。
• Validation is treated as a continuous life cycle, utilizing intensive monitoring to characterize intra-batch variation and ensure a consistent "state of control."
  [中譯] 將驗證視為貫穿產品生命週期的動態過程，利用高強度的製程確認監控，精準掌握批次內部變異，確保生產恆久處於穩定的「受控狀態」。
• Pillar 3: Scientific Integrity in Laboratory Controls: We oversee the Verification of Compendial Methods (USP <1226>) or full validation of proprietary methods.
  [中譯] 支柱三：實驗室管制的科學誠信：我們全程督導藥典分析方法的驗證確認（USP <1226>） or 自主研發方法的完整確效。
• We ensure that every analytical result is supported by raw assay data, adhering to strict data integrity standards where "complete and contemporaneous" is the absolute baseline.
  [中譯] 我們確保每一項化驗分析結果皆備有完整的原始數據支持，嚴格遵循以「完整且即時同步」為絕對底線的數據完整性規範。

6. Conclusion: The Persimmon Engineering Partnership
[中譯] 6. 結語：梁山工程顧問技術夥伴關係

Persimmon Engineering (台南梁山工程顧問有限公司) provides the bridge between Tainan-based manufacturing excellence and the stringent requirements of the global FDA landscape.
[中譯] 梁山工程顧問有限公司(Persimmon Engineering)為台南卓越的製造實力與嚴苛的全球 FDA 法規標準，成功搭建起牢固的技術橋樑。

The Respilon case demonstrates that the FDA is uncompromising regarding technical oversights and data integrity.
[中譯] Respilon 案例深刻說明了 FDA 對於技術疏漏與數據完整性絕無一絲妥協空間。

Regulatory compliance is not a hurdle to be cleared; it is the fundamental foundation for sustainable global market growth.
[中譯] 法規合規絕非一道單次跨越的障礙，而是確保企業得以在全球市場永續增長的核心根基。

When facing the threat of market exclusion, the only path forward is immediate, expert-led action.
[中譯] 面臨面臨市場排除的危急關頭，唯一出路是引進具備實戰經驗的外部專家團隊，立即採取應變行動。

Persimmon Engineering stands ready to defend your license, remediate your systems, and ensure your facility represents the gold standard of pharmaceutical quality.
[中譯] 梁山工程顧問隨時準備為您守護經營執照、整改核心系統，確保您的廠房設施成為全球製藥品質的標竿。

Warning Letter 320-26-69
April 20, 2026
[中譯] 警告信 320-26-69
2026年4月20日

Dear Mr. Zima:
[中譯] 尊敬的 Zima 先生：

Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products.
[中譯] 貴方設施已於美國食品藥物管理局（FDA）註冊為非處方藥（OTC）產品之製造廠。

FDA has reviewed the records you submitted in response to our May 2, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Respilon Production S.R.O, FEI 3018892481, at Prikop 843/4, Brno, Jihomoravsky, Czech Republic.
[中譯] 針對貴方就我們 2025 年 5 月 2 日提出的要求及後續往來信函所提交之紀錄，FDA 已審閱相關文件及其他資產，此乃依據《聯邦食品、藥品和化妝品法案》（FD&C Act）第 704(a)(4) 條，對位於捷克共和國布爾諾的 Respilon Production S.R.O 廠（FEI 3018892481）進行紀錄審查。

This Warning Letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals.
[中譯] 本警告信摘要列舉了針對成品製劑之現行優良製造規範（CGMP）法規的重大違規事項。

See Title 21, Code of Federal Regulations, parts 210 and 211 (21 CFR parts 210 and 211).
[中譯] 參見美國聯邦法規第 21 條第 210 及 211 部分（21 CFR parts 210 and 211）。

Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).
[中譯] 由於貴方在回覆我們第 704(a)(4) 條要求時所陳述的藥品製造、加工、包裝作業或保存方法、廠房設施或管制不符合 CGMP 規範，貴方生產之藥品在法律意義上已構成 FD&C 法案第 501(a)(2)(B) 條所定義之劣藥（21 U.S.C. 351(a)(2)(B)）。

Following our review of records and other information you provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including but not limited to, the following:
[中譯] 在審閱貴方依據 FD&C 法案第 704(a)(4) 條提供的紀錄及其他資訊後，我們發現了重大違規事項，包括但不限於以下各點：

1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).
[中譯] 1. 貴公司未能執行至少一項檢驗以驗證每批藥品組成物的真實身分（鑑別）。貴公司亦未能定期確效並確立原物料供應商分析數據之可靠性（21 CFR 211.84(d)(1) 和 211.84(d)(2)）。

Your response to our request for records under section 704(a)(4) indicated that you do not test the identity of each incoming component used in the manufacture of your drug products, such as (b)(4), before manufacturing.
[中譯] 貴方針對第 704(a)(4) 條紀錄要求的書面回覆指出，您在製造前並未對用於生產藥品的每批進料組成物（例如 (b)(4)）進行身分鑑別檢驗。

In addition, you failed to test each shipment of (b)(4) for (b)(4) contamination before use.
[中譯] 此外，您在投入使用前，亦未能針對每批進口的 (b)(4) 進行 (b)(4) 污染篩檢。

Identity testing for (b)(4) and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of (b)(4).
[中譯] 針對 (b)(4) 及其他特定高風險藥品組成物的鑑別測試，必須包含美國藥典（USP）中規定的限量測試，以確保該原料符合規定的安全限值。

Because you did not perform adequate identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacturing of your drug product.
[中譯] 由於您未能使用可偵測出這些有害不純物的 USP 鑑別測試對每批原物料進行充分的進料檢驗，您無法確保這些原物料在投入藥品生產時的適用性與安全性。

See FDA’s guidance document (b)(4) for help in meeting the CGMP requirements when manufacturing drugs containing ingredients at high risk for (b)(4) contamination.
[中譯] 請參閱 FDA 的行業指南文件 (b)(4)，以協助您在生產含有高 (b)(4) 污染風險成分的藥品時，能完全符合 CGMP 法規之要求。

2. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).
[中譯] 2. 貴公司未能建立並確實遵循合適的書面安定性試驗計畫，以評估藥品的安定性特徵（21 CFR 211.166(a)）。

Your response to our request for records under section 704(a)(4) indicated that you have not performed stability studies for the OTC drug products you manufacture, despite your drug product’s displaying an expiration date on the label.
[中譯] 貴方針對第 704(a)(4) 條紀錄要求的書面回覆顯示，儘管貴方生產的 OTC 藥品標籤上明確標示了末效日期，但您從未對這些產品執行過任何安定性試驗。

Without the appropriate stability studies, you do not have scientific evidence to support whether your drug product’s active ingredient maintains its strength, purity, and quality throughout the shelf life of the product.
[中譯] 缺乏合適的安定性測試支持，您根本沒有任何科學證據能證實產品的主成分在整個架儲期（Shelf life）內，是否依然能維持其應有的含量、純度及品質。

3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).
[中譯] 3. 貴公司未能建立適當的生產與製程管制書面程序，以確保所製造的藥品具備其宣稱或應有的鑑別、含量、品質與純度（21 CFR 211.100(a)）。

Your response to our request for records under section 704(a)(4) indicated that you failed to adequately validate your drug manufacturing processes to demonstrate that they are reproducible and controlled.
[中譯] 貴方針對第 704(a)(4) 條紀錄要求的書面回覆坦承，您未能對藥品製造工藝執行充分的過程確效（製程確效），以證明該製程具備重現性且處於受控狀態。

Process validation evaluates the soundness of design and the state of control of a process throughout its life cycle.
[中譯] 製程確效的目的在於評估製程設計的科學合理性，以及該生產程序在整個產品生命週期中是否持續維持在受控狀態（管制狀態）。

Each significant stage of a manufacturing process must be designed appropriately and must ensure the quality of raw material inputs, in-process materials, and finished drugs.
[中譯] 生產製程中的每個關鍵階段皆必須經過妥善設計，且必須確保投料原物料、半製品（中間產物）及成品製劑的品質。

Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and to evaluate batches to determine whether an initial state of control has been established.
[中譯] 製程性能驗證研究應包含在各關鍵製程階段進行高強度的加強監控與測試，以掌握批次內部的變異特徵，並對各批次進行深度評估，從而判定初始的管制狀態是否已成功確立。

4. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).
[中譯] 4. 貴公司未能建立並以文件記錄檢驗方法的準確度、靈敏度、專一性與重現性（21 CFR 211.165(e)）。

Your response to our request for records under section 704(a)(4) indicated that you failed to adequately validate the test method used to analyze raw materials and finished drug products.
[中譯] 貴方針對第 704(a)(4) 條要求的書面回覆顯示，您未能對分析原物料和成品製劑的檢驗方法實施足夠的確效。

Method validation or verification has not been completed for the active ingredient assay testing for (b)(4).
[中譯] 針對 (b)(4) 的主成分含量測定法，至今尚未完成基本的方法確效或藥典方法驗證。

Your analytical method does not demonstrate specificity, accuracy, precision, and robustness.
[中譯] 貴方所使用的分析方法完全無法證明其專一性、準確度、精密度與健壯性。

Additionally, it appears that your firm is not performing microbiological testing for each batch of your drug products before release.
[中譯] 批外，貴公司顯然未能在放行前，對每批藥品進行法定的微生物檢驗。

In your response, you state that your drug product has low (b)(4) at less than (b)(4) and that microbial proliferation is not possible.
[中譯] 您在回覆中辯稱，該藥品的水活性極低（小於 (b)(4)），因此微生物繁殖「絕無可能」。

However, you have not validated your overall manufacturing process or conducted stability studies to determine if microbial contamination proliferates throughout the shelf life of the product.
[中譯] 然而，您並未對整體製造製程進行確效，亦未執行任何安定性測試，以確認微生物污染在產品整個架儲期內是否會發生增殖。

You have not provided a comprehensive microbial risk assessment of your manufacturing steps, such as in-process hold times, storage conditions, and the microbial load of your (b)(4) ingredients.
[中譯] 貴方並未能針對各個生產步驟提供完整的微生物風險評價，例如半製品保存時間、儲存條件、以及所投入之 (b)(4) 成分的初始負荷菌（Bioburden）。

The statement in your response that you intend to conduct reduced microbial testing is insufficient, based on the limited information you provided and the lack of documentation to support your approach.
[中譯] 基於您所提供的極有限資訊，且完全缺乏任何支持性文件，您在回覆中宣稱「計畫實施減免微生物測試」的主張是完全站不住腳的。

5. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (211.194(a)).
[中譯] 5. 貴公司未能確保實驗室紀錄中，包含來自所有必要測試的完整數據，以確認產品符合既定的規格與標準（21 CFR 211.194(a)）。

Your response to our request for records under section 704(a)(4) indicated that your finished drug product’s Certificate of Analysis did not provide an individual test result for (b)(4) content.
[中譯] 貴方針對第 704(a)(4) 條要求的書面回覆表明，貴方成品的檢驗報告書（COA）中，並未登載 (b)(4) 含量的具體檢測數值。

The “Batch Production” record that you provided as your Certificate of Analysis states “PASSED” in the “Conformity” section but does not provide an assay result.
[中譯] 您作為分析證明書遞交的「批生產紀錄」中，在「符合性」欄位僅空洞地寫著「合格（PASSED）」，卻完全沒有提供任何定量分析檢測結果。

CGMP Consultant Recommended
[中譯] 強烈建議引進 CGMP 合規顧問

Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements.
[中譯] 鑑於在貴公司發現的違規行為之本質，您應聘請符合 21 CFR 211.34 規定之資格的獨立外部顧問，以全面評估您的營運狀況並協助貴廠達到 CGMP 合規標準。

The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.
[中譯] 該合規顧問在您向 FDA 申請恢復廠規合規狀態之前，必須先針對貴廠的整體營運執行全方位的「六大系統稽核」，並嚴格評估所有矯正與預防措施（CAPA）的完成度與實質有效性。

Conclusion
[中譯] 結論

The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility.
[中譯] 本信件中引述的違規事項，並非旨在詳列貴廠內存在的所有不合規行為。

You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.
[中譯] 貴方有全權責任對任何違規事項進行深入調查並找出其根本原因，並杜絕其再次發生或防止其他不合規事件的出現。

Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP.
[中譯] 請務必立即矯正所有違規事項。在所有缺失被完全整改且經我們確認符合 CGMP 標準之前，FDA 將依法凍結所有將貴廠列為藥品製造商的新申請案或補充申請案之批准。

We may inspect to verify that you have completed corrective actions to any violations.
[中譯] 我們可能會啟動現場實地重檢，以驗證貴方是否確實執行了針對各項違規的矯正行動。

Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Respilon Production S.R.O., Prikop 843/4, Brno, Jihomoravsky, Czech Republic into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).
[中譯] 若未能妥善整改這些不合規缺失，將導致 FDA 依據 FD&C 法案第 801(a)(3) 條（21 U.S.C. 381(a)(3)），拒絕將 Respilon Production S.R.O.（位於捷克共和國布爾諾）所製造的任何產品輸入至美國。在此法令授權下，凡外觀或製程看似構成「劣藥」的品項將直接遭到關口扣押或拒絕入境，因其所使用的製造方法與控制程序顯然不符合 FD&C 法案第 501(a)(2)(B) 條所定義之 CGMP 規範。

This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.
[中譯] 本信旨在正式通知貴方我們的查核發現，並給予您更正上述缺失的應變機會。在收到本信函後，您必須在 15 個工作天內，以書面形式回覆本辦公室。

Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices.
[中譯] 請具體敘述您已採取了哪些具體行動來導正違規事項，並防止其再度發生。在回覆信函中，您可以附帶提供其他補充文件，供我們在持續評估貴廠作業與品質實踐時進行審酌。

If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.
[中譯] 若您無法在 15 個工作天內徹底完成所有矯正行動，請詳述延誤的合理原因，並提交一份明確的「整改完成時程表」。

Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3018892481 and ATTN: Erika V. Butler.
[中譯] 請將您的電子郵件回覆發送至 CDER-OC-OMQ-Communications@fda.hhs.gov。請務必在回覆郵件中註明您的工廠機構代碼 FEI 3018892481，並註明由 Erika V. Butler 收啟。

Sincerely,
/S/
Francis Godwin
Director
Office of Manufacturing Quality
Office of Compliance
Center for Drug Evaluation and Research
[中譯] 順頌商祺，
/經簽署/
Francis Godwin
主任
製造品質辦公室
合規辦公室
藥品評估與研究中心（CDER）